Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.69 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.68 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605049 | 0.90 | GRM3 (0.73) | GRM3FOLH1NAALAD2 | |
| SCHEMBL12145013 | 0.87 | GRM3 (0.73) | GRM3FOLH1NAALAD2 | |
| SCHEMBL20529841 | 0.84 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5051325 | 0.84 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL11959173 | 0.84 | GCLC (0.54) | GRM3FOLH1 | |
| SCHEMBL1374889 | 0.84 | GRM3 (0.69) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1377500 | 0.83 | GRM3 (0.79) | GRM3FOLH1NAALAD2 | |
| SCHEMBL4135913 | 0.82 | GRM3 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL10134655 | 0.81 | FOLH1 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL15278193 | 0.81 | FOLH1 (1.00) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6384022-B1 | ENZYME INHIBITORS | GUILFORD PHARMACEUTICALS INC. | 2002-05-07 | — | — | US | claimed |
| JP-2001527084-A | — | — | 2001-12-25 | — | — | JP | claimed |
| EP-1044206-A1 | PRODRUGS OF NAALADASE INHIBITORS | Guildford Pharmaceuticals Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1999033848-B1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARM INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20070041934-A1 | Dendrimer based compositions and methods of using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070041934-A1 | Dendrimer based compositions and methods of using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-6028216-A | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-22 | — | — | US | disclosed |